Drug Industry Avoids FDA's "Blunt Tools" With Safe Use Initiative Progress

Efforts by firms and other pharmaceutical industry stakeholders to drive FDA's Safe Use Initiative agenda lower the likelihood of the agency intervening with enforcement action, according to Principal Deputy Commissioner Josh Sharfstein